Claris Lifesciences sells injectables unit to Baxter
Shital Jibhe / 28 Jul 2017
Claris Lifesciences has sold its generic injectables business to pharmaceutical major Baxter International Inc. for USD 625 million (Rs 4,013 crore).
Claris Lifesciences has sold its generic injectables business to pharmaceutical major Baxter International Inc. for USD 625 million (Rs 4,013 crore).
The company’s transaction was financed through a combination of cash on hand and debt, prior to which the deal was held up after clearance of the US Federal Trade Commission as the acquisition is anti-competitive. It only got a go-ahead after related parties agreed to sell rights
Claris Lifesciences will now identify the most efficient method of transferring a majority of the proceeds from the sale to its shareholders. The process of transferring the proceeds will be decided before October 15.
Shares of Claris Lifesciences were trading at Rs 384.4 with reduction of 1.64% at 0926 hours.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.